Cell Cure Neurosciences was founded as a subsidiary of the Singapore-based ES Cell International (ESI). In 2010, BioTime acquired a majority interest in Cell Cure Neurosciences upon the acquisition of ESI. That transaction, along with the other acquisitions of BioTime, such as the stem cell assets of Geron Corporation, have resulted in an international consolidation of critical intellectual property rights within the BioTime family of companies. In 2017, Cell Cure Neurosciences became a wholly owned subsidiary of BioTime. The company has continued to grow and currently has over 30 employees directly involved in product development and manufacturing. The company has recently completed the construction of a cGMP manufacturing facility for the production of OpRegen and other cell therapy products.